GeneFerm Biotechnology Co., Ltd. (TPEX:1796)
Taiwan · Delayed Price · Currency is TWD 27.55
+0.65 (2.42%)
Nov 10, 2026, 1:21 PM CST
GeneFerm Biotechnology Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,142 | 2,000 | 1,949 | 3,089 | 2,774 | 1,809 | |
Market Cap Growth | -44.68% | 2.66% | -36.91% | 11.36% | 53.33% | 122.87% |
Enterprise Value | 1,194 | 2,053 | 2,085 | 3,172 | 2,842 | 1,711 |
Last Close Price | 27.55 | 47.23 | 46.01 | 70.65 | 62.56 | 40.46 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 153.52 | 69.31 | - | 24.79 | 29.68 | 31.51 |
PS Ratio | 1.71 | 2.95 | 3.74 | 3.89 | 4.38 | 3.46 |
PB Ratio | 1.46 | 2.45 | 2.47 | 3.46 | 3.34 | 2.42 |
P/TBV Ratio | 1.47 | 2.45 | 2.48 | 3.47 | 3.34 | 2.42 |
P/FCF Ratio | 72.16 | 26.36 | - | 25.66 | - | - |
P/OCF Ratio | 20.88 | 20.14 | 240.87 | 16.23 | 22.65 | 16.12 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.78 | 3.03 | 4.00 | 4.00 | 4.48 | 3.28 |
EV/EBITDA Ratio | 15.50 | 18.09 | 55.02 | 14.46 | 19.58 | 14.53 |
EV/EBIT Ratio | 147.64 | 44.55 | - | 20.66 | 27.86 | 21.70 |
EV/FCF Ratio | 75.44 | 27.05 | - | 26.35 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.35 | 0.40 | 0.30 | 0.14 | 0.22 | 0.59 |
Debt / EBITDA Ratio | 3.57 | 2.69 | 5.23 | 0.56 | 1.19 | 3.52 |
Debt / FCF Ratio | 17.38 | 4.27 | - | 1.06 | - | - |
Net Debt / Equity Ratio | 0.07 | 0.05 | 0.14 | 0.01 | 0.10 | -0.14 |
Net Debt / EBITDA Ratio | 0.69 | 0.39 | 2.97 | 0.03 | 0.55 | -0.87 |
Net Debt / FCF Ratio | 3.27 | 0.58 | -7.86 | 0.06 | -0.52 | 3.14 |
Asset Turnover | 0.54 | 0.56 | 0.45 | 0.67 | 0.51 | 0.45 |
Inventory Turnover | 2.62 | 2.73 | 2.64 | 3.41 | 3.20 | 2.94 |
Quick Ratio | 2.16 | 2.48 | 1.78 | 1.25 | 0.93 | 1.50 |
Current Ratio | 3.63 | 3.75 | 3.07 | 2.09 | 1.56 | 1.78 |
Return on Equity (ROE) | 0.92% | 3.60% | -2.68% | 14.46% | 11.84% | 10.04% |
Return on Assets (ROA) | 0.41% | 2.37% | -1.85% | 8.12% | 5.09% | 4.29% |
Return on Invested Capital (ROIC) | 0.82% | 4.35% | -3.82% | 13.77% | 11.11% | 10.78% |
Return on Capital Employed (ROCE) | 0.80% | 4.10% | -3.40% | 15.60% | 10.70% | 8.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.65% | 1.44% | -1.16% | 4.04% | 3.37% | 3.17% |
FCF Yield | 1.39% | 3.79% | -0.73% | 3.90% | -5.62% | -1.80% |
Dividend Yield | 2.54% | 1.45% | - | 2.69% | 2.24% | 2.25% |
Payout Ratio | 398.82% | - | - | 49.90% | 44.36% | 5.90% |
Buyback Yield / Dilution | 2.12% | -0.11% | 0.36% | 2.26% | 8.00% | -65.83% |
Total Shareholder Return | 4.66% | 1.34% | 0.36% | 4.95% | 10.24% | -63.58% |